major insurance changes are coming to glp 1 drugs CMS Issues Coverage Guidance on GLP-1 Anti-Obesity GLP-1 Antagonists Increase Plan Drug – The GLP-1 Access Gap: Mapping

Strategic partnerships and supply chain resilience will be essential

de, Weijer, T

But with so many options on the market a lot of which are from shady companies making impossible promises how do you know which ones are effective and, most importantly, safe

By influencing this master switch, Berberine supports healthy glucose metabolism and promotes efficient energy utilization across multiple systems

Three developments are converging to make 2026 a pivotal year for dermatology compounding: the FDAs peptide reclassification is restoring access to key molecules used in skin and wound healing, tightening quality standards are separating accredited pharmacies from the rest, and digital prescribing platforms are finally eliminating the operational friction that has kept many dermatologists from incorporating compounding into their standard workflow